OxRML/AgentSLR huggingface dataset:
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 3.1876 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.6095 - 3.6759 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Mo'orea, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.3367 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.1522 - 2.5076 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Tuamotu-Gambier, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.0691 No units (Central)
Exponent (base 10): 0
Uncertainty: 1.2613 - 4.3165 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Marquesas Islands, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.0274 No units (Central)
Exponent (base 10): 0
Uncertainty: 1.9068 - 2.1397 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Australes, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 3.1985 No units (Central)
Exponent (base 10): 0
Uncertainty: 3.0727 - 3.3196 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: Federated States of Micronesia
Location: Yap Island
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - incubation period (inverse parameter) (Human delay)
Value: 0.2253 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.161 - 0.2896 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Tahiti, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - incubation period (inverse parameter) (Human delay)
Value: 0.0836 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.0589 - 0.1083 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Mo'orea, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - incubation period (inverse parameter) (Human delay)
Value: 0.0865 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.071 - 0.102 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Tuamotu-Gambier, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - incubation period (inverse parameter) (Human delay)
Value: 0.25 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.1826 - 0.3174 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Australes, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value: 0.0833 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.06 - 0.1066 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Sous-le-vent Islands, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value: 0.0833 Days (Central)
Exponent (base 10): 0
Uncertainty: 0.0263 - 0.1403 (95% CI)
Statistical approach: Estimated model parameter
Population: General population, sex: , ages  to 
Country: France
Location: Marquesas Islands, French Polynesia
Setting: Population based, Unspecified
Study period: Oct 2013 - Mar 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 57 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 172 / 302 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Post-partum
Population: Other, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Unspecified
Sample size: 302
Study period: Sep 2017 - Nov 2017
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.23 No units (Mean)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Disaggregated by: Other
Reproduction number method: Next generation matrix Other
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, 
Study period: Unspecified
Parameter: Severity - case fatality rate (CFR) (Severity)
Value: 8.4 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Other
Numerator/denominator: 35 / 418 (method: Unspecified)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Colombia
Setting: Population based, Both urban and rural areas
Sample size: 418
Study period: Jul 2015 - Oct 2017
Parameter: Human delay - NAAT-detectable infection to Seroconversion (IgM) (Human delay)
Value: 7.7 Days (Mean)
Exponent (base 10): 0
Uncertainty: 6.1 - 9.2 (95% CI)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: United States
Location: Florida, Puerto Rico, Texas, Nevada
Setting: Population based, 
Sample size: 25
Study period: 6 Jul 2016 - 7 Mar 2017
Parameter: Human delay - NAAT-detectable infection to Seroreversion (IgM) (Human delay)
Value: 237 Days (Mean)
Exponent (base 10): 0
Uncertainty: 128.7 - 459.5 (95% CI)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: United States
Location: Florida, Puerto Rico, Texas, Nevada
Setting: Population based, 
Sample size: 25
Study period: 6 Jul 2016 - 7 Mar 2017
Parameter: Seroprevalence - Biotinylated-EDIII antigen capture ELISA (Seroprevalence)
Value: 18 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 98 / 547 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 9 to 14
Country: Philippines
Location: Balamban and Bogo City in Cebu Province
Setting: Other, Both urban and rural areas
Sample size: 547
Study period: 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 79.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 180 / 227 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Unspecified, ages 9 to 16
Country: Honduras
Setting: Other, Unspecified
Sample size: 227
Study period: Jun 2011 - Mar 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 47.6 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 339 / 712 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Unspecified, ages 9 to 16
Country: Colombia
Setting: Other, Unspecified
Sample size: 712
Study period: Jun 2011 - Mar 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 38.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 103 / 269 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Unspecified, ages 9 to 16
Country: Mexico
Setting: Other, Unspecified
Sample size: 269
Study period: Jun 2011 - Mar 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 25 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 23 / 92 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Unspecified, ages 9 to 16
Country: United States
Location: Puerto Rico
Setting: Other, Unspecified
Sample size: 92
Study period: Jun 2011 - Mar 2012
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 20.5 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 49 / 239 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Unspecified, ages 9 to 16
Country: Brazil
Setting: Other, Unspecified
Sample size: 239
Study period: Jun 2011 - Mar 2012
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 3 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 196 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 19 to 35
Country: Brazil
Location: Maranhao state
Setting: Hospital based, 
Sample size: 196
Study period: Apr 2017 - Jun 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 17.3 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 34 / 196 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 19 to 35
Country: Brazil
Location: Maranhao state
Setting: Hospital based, 
Sample size: 196
Study period: Apr 2017 - Jun 2018
Parameter: Human delay - infectious period (inverse parameter) (Human delay)
Value: 0.17 Per day (Median)
Exponent (base 10): 0
Uncertainty: 0.1 - 0.23 (95% CrI)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Location: Rio de Janeiro
Setting: Population based, Urban area
Study period: 2016
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 2.75 No units (Central)
Exponent (base 10): 0
Uncertainty: 2.53 - 2.98 (95% CI)
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: France
Location: French Polynesia
Setting: Population based, Unspecified
Study period: 2013
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 15 - 94
Statistical approach: Observed sample statistic
Disaggregated by: Time
Population: Persons under investigation, sex: Both, ages 16 to 
Country: Brazil
Setting: Hospital based, 
Study period: Jan 2016 - Sep 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 15 Percentage (%) ()
Exponent (base 10): 0
Case definition: Confirmed
Numerator/denominator: 11 / 72 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Other, Time
Population: Persons under investigation, sex: Both, ages  to 
Country: Brazil
Location: São Paulo state
Setting: Hospital based, 
Sample size: 72
Study period: Jan 2016 - Sep 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Bounds: 6 - 86
Statistical approach: Observed sample statistic
Disaggregated by: Time
Population: Persons under investigation, sex: Both, ages 16 to 
Country: Brazil
Location: São Paulo state
Setting: Hospital based, 
Study period: Jan 2016 - Sep 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 11 / 1021 (method: Naive)
Seroprevalence adjustment: Naive
Disaggregated by: Age
Population: General population, sex: Both, ages  to 
Country: Solomon Islands
Setting: Community based, 
Study period: Apr 2018 - Nov 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 86.8 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 99 / 114 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Colombia
Location: Risaralda
Setting: Hospital based, 
Sample size: 115
Study period: 22 Nov 2017 - 5 Jun 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 2.63 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 3 / 114 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Colombia
Location: Risaralda
Setting: Other, 
Sample size: 115
Study period: 22 Nov 2016 - 5 Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.58 No units (Median)
Exponent (base 10): 0
Uncertainty: 1.56 - 1.59 (95% CrI)
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Nicaragua
Location: Managua
Setting: Population based, 
Study period: 2016
Parameter: Human delay - infectious period (Human delay)
Value: 4.8 Days (Median)
Exponent (base 10): 0
Uncertainty: 4.3 - 5.4 (95% CrI)
Statistical approach: Estimated model parameter
Population: General population, sex: Unspecified, ages  to 
Country: Nicaragua
Location: Managua
Setting: Population based, 
Study period: 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 1 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 21 / 2013 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Children, sex: Both, ages 0 to 0
Country: Vietnam
Location: Nha Trang
Setting: Hospital based, Unspecified
Sample size: 2013
Study period: jul 2017 - Sep 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0.5 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 11 / 21 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Children, sex: Both, ages 0 to 0
Country: Vietnam
Location: Nha Trang
Setting: Hospital based, Unspecified
Sample size: 2013
Study period: Jul 2017 - Sep 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 62 Percentage (%) (Mean)
Exponent (base 10): 0
Bounds: 33.3 - 75
Case definition: Lab confirmed
Numerator/denominator: 85 / 136 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age
Population: Pregnant women, sex: Female, ages  to 
Country: Mexico
Location: Chiapas
Setting: Hospital based, 
Sample size: 136
Study period: Feb 2019 - Aug 2019
Parameter: Human delay - Exposure/Infection to Recovery/non-Infectiousness (Human delay)
Value: 9 Days (Median)
Exponent (base 10): 0
Uncertainty: 8 - 10 (IQR)
Statistical approach: Observed sample statistic
Population: Unspecified, sex: Unspecified, ages  to 
Country: France
Location: Marseille, La Reunion
Setting: Unspecified, 
Study period: Unspecified
Parameter: Mosquito delay - extrinsic incubation period (Mosquito)
Value:  Days (Mean)
Exponent (base 10): 0
Bounds: 17.8 - 24.2
Statistical approach: Estimated model parameter
Disaggregated by: Level of exposure
Population: Unspecified, sex: Unspecified, ages  to 
Country: France
Location: Marseille, La Reunion
Setting: Unspecified, 
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:   (Central)
Exponent (base 10): 0
Numerator/denominator: 18 / 20 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Vietnam
Location: Ho Chi Minh City
Setting: Hospital based, Both urban and rural areas
Sample size: 20
Study period: Mar 2016 - Nov 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:   (Central)
Exponent (base 10): 0
Numerator/denominator: 1 / 21 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Children, sex: Both, ages  to 
Country: Vietnam
Location: Ho Chi Minh City
Setting: Hospital based, Both urban and rural areas
Sample size: 21
Study period: Mar 2016 - Nov 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 55.8 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 324 / 581 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Pernambuco State
Setting: Hospital based, Both urban and rural areas
Sample size: 581
Study period: Dec 2015 - Jun 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 10.2 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 71 / 694 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Pernambuco State
Setting: Hospital based, Both urban and rural areas
Sample size: 694
Study period: Dec 2015 - Jun 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 8.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 20 / 240 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Pernambuco State
Setting: Hospital based, Both urban and rural areas
Sample size: 240
Study period: Dec 2015 - Jun 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 9 / 404 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Juazeiro do Norte
Setting: Community based, 
Sample size: 404
Study period: Jun 2018 - Dec 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 216 / 404 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages  to 
Country: Brazil
Location: Juazeiro do Norte
Setting: Community based, 
Sample size: 404
Study period: Jun 2018 - Dec 2018
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 837 / 6654 (method: )
Seroprevalence adjustment: Naive
Disaggregated by: Other
Population: Pregnant women, sex: Female, ages 12 to 52
Country: Guyana
Location: Cayenne, Kourou, Saint Laurent
Setting: Hospital based, Urban area
Sample size: 6654
Study period: Jan 2016 - Dec 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 16.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 12 to 52
Country: Guyana
Location: Cayenne, Kourou, Saint Laurent
Setting: Hospital based, Urban area
Study period: Jan 2016 - Dec 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 9.82 Percentage (%) (Unspecified)
Exponent (base 10): 0
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 12 to 52
Country: Guyana
Location: Cayenne, Kourou, Saint Laurent
Setting: Hospital based, Urban area
Study period: Jan 2016 - Dec 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value:  Percentage (%) (Central)
Exponent (base 10): 0
Bounds: 0 - 14
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Method
Population: Children, sex: , ages  to 
Country: Guatemala
Location: Coastal lowlands of SW Guatemala
Setting: Population based, Rural area
Sample size: 196
Study period: Oct 2015 - Nov 2015
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value:  Percentage (%) (Central)
Exponent (base 10): 0
Bounds: 19 - 40
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Method
Population: Children, sex: , ages  to 
Country: Guatemala
Location: Coastal lowlands of SW Guatemala
Setting: Population based, Rural area
Sample size: 186
Study period: Jan 2016 - Feb 2016
Parameter: Seroprevalence - NS1 BOB ELISA (Seroprevalence)
Value: 10 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 20 / 196 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: , ages  to 
Country: Guatemala
Location: Coastal lowlands of SW Guatemala
Setting: Population based, Rural area
Sample size: 196
Study period: Oct 2015 - Nov 2015
Parameter: Seroprevalence - NS1 BOB ELISA (Seroprevalence)
Value: 37 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 69 / 186 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: , ages  to 
Country: Guatemala
Location: Coastal lowlands of SW Guatemala
Setting: Population based, Rural area
Sample size: 186
Study period: Jan 2016 - Feb 2016
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 0.19 No units (Median)
Exponent (base 10): 0
Uncertainty: 0.05 - 0.48 (95% CI)
Bounds: 0 - 0.29
Statistical approach: Estimated model parameter
Disaggregated by: Region
Reproduction number method: Ross-Macdonald formula Vector-human
Population: General population, sex: , ages  to 
Country: United States
Location: Texas
Setting: Population based, Both urban and rural areas
Study period: Jan 2016 - Jan 2017
Parameter: Reproduction number (Effective, Re) (Reproduction number)
Value: 2.2 No units (Central)
Exponent (base 10): 0
Bounds: 1.1 - 3.3
Disaggregated by: Time
Reproduction number method: Next generation matrix 
Population: Persons under investigation, sex: , ages  to 
Country: Brazil
Location: Northeastern
Setting: Population based, 
Study period: Jan 2015 - Nov 2016
Parameter: Attack rate (Attack rate)
Value:  Unspecified (Unspecified)
Exponent (base 10): 0
Bounds: 0.219 - 0.285
Disaggregated by: Method
Population: Persons under investigation, sex: , ages  to 
Country: Brazil
Location: Northeastern
Setting: Population based, 
Study period: Jan 2015 - Nov 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 12 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 26 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Disaggregated by: Other, Symptoms
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Mexico
Location: Monterrey City
Setting: Hospital based, Urban area
Sample size: 26
Study period: 1 Aug 2017 - 30 Jun 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 8 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 9 / 113 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Disaggregated by: Other, Symptoms
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Mexico
Location: Monterrey City
Setting: Hospital based, Urban area
Sample size: 113
Study period: 1 Aug 2017 - 30 Jun 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 8 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 8 / 100 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Kenya
Location: Kokipei, West Pokot
Setting: Population based, Unspecified
Sample size: 100
Study period: Feb 2016